Korro Bio Doses First Patient In Krro-121 Phase 1/2 Trial
Korro Bio, Inc. announced that the first cohort of patients has been dosed in its Phase 1/2 clinical trial for Krro-121.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Korro Bio doses first cohort in Phase 1/2 trial for KRRO-121
Korro Bio has begun dosing the first cohort in its ANCHOR Phase 1/2 program for KRRO-121, an RNA-editing oligonucleotide for hyperammonemia. SAD/MAD studies are underway in healthy volunteers in Australia.